Aclaris Therapeutics, Inc. (ACRS) vs BrainsWay Ltd. (BWAY)
Aclaris Therapeutics, Inc. and BrainsWay Ltd. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ACRS vs BWAY, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Aclaris Therapeutics, Inc. (ACRS) | BrainsWay Ltd. (BWAY) | |
|---|---|---|
| Market cap | $0.6B | $0.6B |
| Revenue (latest FY) | $7.83M | $52.23M |
| Net income (latest FY) | $-64.92M | $7.63M |
| Revenue growth (5y CAGR) | 3.8% | 24.3% |
| Net margin | -829.6% | 14.6% |
| Return on equity | -63.0% | 10.4% |
| P/E ratio | — | 67.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | Yes |
Performance — ACRS vs BWAY
Total returns from monthly split- and dividend-adjusted closes; 52-week range from the latest quote. Past performance is not a prediction.
| Aclaris Therapeutics, Inc. (ACRS) | BrainsWay Ltd. (BWAY) | |
|---|---|---|
| 1-year return | 202.1% | 127.2% |
| 3-year return | -58.6% | 1210.5% |
| 5-year return | -75.6% | 192.9% |
| 10-year return | -76.8% | — |
| 52-week range | $1.34–$5.15 | $5.33–$17.35 |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full ACRS vs BWAY breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ACRS's full financials → Open BWAY's full financials →More comparisons
Frequently asked questions
Which is bigger, ACRS or BWAY?
Aclaris Therapeutics, Inc. is larger by market capitalization — $0.6B versus $0.6B.
Which grows faster, ACRS or BWAY?
Over the last five fiscal years, BrainsWay Ltd. grew revenue faster — 24.3%/yr versus 3.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
ACRS fundamentals → · BWAY fundamentals → · All 1,500+ companies → · Free screener →